News & Updates

In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.

A 16-week dosing interval for the IL-23 inhibitor guselkumab appears to sufficiently keep psoriasis controlled among patients who have achieved complete skin clearance shortly after starting standard treatment with the drug, according to the phase IIIb GUIDE clinical trial.

A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.